UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 23, 2024
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
||
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650 ) 391-9740
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Following approval by the Board of Directors (the “Board”) of BridgeBio Pharma, Inc. (the “Company”), Thomas Trimarchi was appointed as the Company’s
President and Chief Operating Officer, and Neil Kumar, Ph.D. stepped down as President, in each case, effective as of July 23, 2024. Mr. Trimarchi was appointed to serve as President and Chief Operating Officer until his successor is duly elected
and qualified, or until his earlier death, resignation, retirement, removal or termination of office. Dr. Kumar will continue to serve and perform his duties as a director and the Company’s Chief Executive Officer.
Dr. Trimarchi, age 39, prior to this appointment, served as the Company’s Chief Product Officer from April 2018 to July 2024. He has also served on the
board of directors of the Company’s affiliate ML Bio Solutions, Inc. since November 2021. Prior to joining the Company, Dr. Trimarchi worked in corporate strategy at Regeneron Pharmaceuticals, Inc. from 2017 to 2018, prior to that he was an equity
analyst in the Global Investment Research division at Goldman Sachs from 2015 to 2017. Dr. Trimarchi earned his B.S. in Biology from the University of Vermont in 2007, and his Ph.D. in Molecular Oncology and Immunology, Cell and Molecular Biology
from New York University in 2014.
There are no arrangements or understandings between Mr. Trimarchi and any other persons in connection with his appointment as President and Chief
Operating Officer. He has no family relationships with any of the Company’s directors or executive officers, and he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as
amended.
| Item 7.01 |
Regulation FD Disclosure.
|
On July 23, 2024, the Company issued a press release announcing Mr. Trimarchi’s appointment as President and Chief Operating
Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press release dated July 23, 2024
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
BRIDGEBIO PHARMA, INC.
|
||
|
Date: July 23, 2024
|
By:
|
/s/ Brian C. Stephenson
|
|
Name: Brian C. Stephenson
|
||
|
Title: Chief Financial Officer
|
Exhibit 99.1
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO)
(“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will
assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D.
In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business
success at BridgeBio. He will lead cross-functional activities to develop a centralized operation across the late-stage pipeline prioritizing efficiency, rigor, and scale.
“I’m thrilled to partner with Tom in his new role, and excited to continue to learn from him. Tom thinks independently, puts patients first,
understands that every minute counts for the patients we serve, and lets science and data dictate his decision-making,” said Dr. Kumar. “He has been a tremendous part of building BridgeBio into what it is today, and I look forward to seeing his
continued growth as a leader enable us to have ever-better impact on patients.”
Dr. Trimarchi has served in roles of increasing responsibility since joining BridgeBio in 2018, most recently as the Chief Product Officer. He is
also a board member of ML Bio Solutions, a BridgeBio affiliate focused on developing BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), since November 2021. Prior to joining the company, Dr. Trimarchi worked at Regeneron
Pharmaceuticals, Inc., and Goldman Sachs after receiving his Ph.D. in Molecular Oncology and Immunology from New York University.
1
“I am inspired every day by the work the teams are doing at BridgeBio to serve patients and families impacted by genetic diseases. The BridgeBio team
is deeply passionate about the meaningful work they are doing to create and deliver transformative medicines with a patients-first mindset,” said Dr. Trimarchi. “I feel lucky to be stewarding our mission alongside Neil and Brian. We are just
getting started on delivering life-changing treatments for as many patients as possible.”
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to
discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and
its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650) 789-8220
2